Drug Profile
BMS 986242
Alternative Names: BMS-986242Latest Information Update: 29 Sep 2020
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 29 Sep 2020 No development reported - Phase-I/II for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (pipeline, September 2020)
- 27 Nov 2017 Phase-I/II clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT03351231)
- 24 Nov 2017 Bristol-Myers Squibb plans a phase I/IIa trial for Cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT03351231)